Contraindicated. Coadministration of doravirine with a powerful CYP3A inducer could decrease doravirine plasma concentrations and/or effects. Probable for loss of virologic response and attainable resistance to doravirine.pentobarbital will minimize the extent or impact of armodafinil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/